Outwardly lean people who have type 2 diabetes have increased intra-organ fat, reductions in which occur in line with weight loss-induced diabetes remission, say researchers.
A post-hoc analysis of SUSTAIN 10 indicates that people with type 2 diabetes stand to gain from GLP-1 receptor agonist use even if they are already using an SGLT2 inhibitor.
EASD 2021 interviews
10-08-2021 | EASD 2021 | Conference coverage | Video
Parth Narendran gives his highlights of the ADA/EASD type 1 diabetes management consensus report, and explains how it can support clinicians to deliver improved services for their patients.
10-01-2021 | EASD 2021 | Conference coverage | Video
Pinar Topsever comments on the TriMaster study of a stratified medicine approach to second- and third-line treatment for type 2 diabetes, and discusses what the results mean for primary care practice.
10-01-2021 | EASD 2021 | Conference coverage | Video
Anne Peters talks about the goals of the ADA/EASD type 1 diabetes management consensus report, the issues to urgently address, and the joys of being part of a trans-Atlantic collaboration.
10-01-2021 | EASD 2021 | Conference coverage | Video
